Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

EQRx

2 Disclosed Funding Rounds $700,000,000

0 Participating Investments


Pharmaceutical, Health Care, Biotechnology, Medical

EQRx is a biotechnology company that focuses on re-engineering the process of drug discovery to make them affordable.

Cambridge, Massachusetts, United States, North America (US)

Organizations in Cambridge in Pharmaceutical,
Organizations in Cambridge in Health Care,
Organizations in Cambridge in Biotechnology,
Organizations in Cambridge in Medical,
Organizations in Massachusetts in Pharmaceutical,
Organizations in Massachusetts in Health Care,
Organizations in Massachusetts in Biotechnology,
Organizations in Massachusetts in Medical,
Organizations in United States in Pharmaceutical,
Organizations in United States in Health Care,
Organizations in United States in Biotechnology,
Organizations in United States in Medical,
Organizations in North America in Pharmaceutical,
Organizations in North America in Health Care,
Organizations in North America in Biotechnology,
Organizations in North America in Medical

Investors in Cambridge in Pharmaceutical,
Investors in Cambridge in Health Care,
Investors in Cambridge in Biotechnology,
Investors in Cambridge in Medical,
Investors in Massachusetts in Pharmaceutical,
Investors in Massachusetts in Health Care,
Investors in Massachusetts in Biotechnology,
Investors in Massachusetts in Medical,
Investors in United States in Pharmaceutical,
Investors in United States in Health Care,
Investors in United States in Biotechnology,
Investors in United States in Medical,
Investors in North America in Pharmaceutical,
Investors in North America in Health Care,
Investors in North America in Biotechnology,
Investors in North America in Medical

Greater Boston Area (0 Investors) (0 Startups), New England (0 Investors) (0 Startups), East Coast (0 Investors) (0 Startups), Northeastern US (0 Investors) (0 Startups)

Founded date 01, 2019

Founders Sandra Horning, Peter Bach, Alexis Borisy

Operating Status Active

Funding Stage Early Stage Venture

Last Funding Type Series B

Company Type For Profit


Twitter Link

LinkedIN Link

Wikipedia Link

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Date Round Raised Lead
January, 11, 2021 Series B $500,000,000 -------
January, 12, 2020 Series A $200,000,000 GV

EQRx Investors (15)

Investor Lead? Round Participating Raise Date Partners
Casdin Capital No Series B $500,000,000 January, 11, 2021 -------
GV No Series B $500,000,000 January, 11, 2021 -------
Andreessen Horowitz No Series B $500,000,000 January, 11, 2021 -------
Section 32 No Series B $500,000,000 January, 11, 2021 -------
ARCH Venture Partners No Series B $500,000,000 January, 11, 2021 -------
Nextech Invest No Series B $500,000,000 January, 11, 2021 -------
Arboretum Ventures No Series B $500,000,000 January, 11, 2021 -------
Bain Capital Life Sciences No Series B $500,000,000 January, 11, 2021 -------
Casdin Capital No Series A $200,000,000 January, 12, 2020 -------
ARCH Venture Partners No Series A $200,000,000 January, 12, 2020 -------
Arboretum Ventures No Series A $200,000,000 January, 12, 2020 -------
Section 32 No Series A $200,000,000 January, 12, 2020 -------
Nextech Invest No Series A $200,000,000 January, 12, 2020 -------
GV Yes Series A $200,000,000 January, 12, 2020 -------
Andreessen Horowitz No Series A $200,000,000 January, 12, 2020 -------